Skip to content

Effects of WBV Associated With IMT on Inflammatory Markers, Body Composition, Muscle Strength and Thickness

Effects of Whole Body Vibration Associated With the Inspiratory Muscle Training Program on Inflammatory Markers, Body Composition, Muscle Strength and Thickness

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03689322
Enrollment
42
Registered
2018-09-28
Start date
2018-10-01
Completion date
2019-07-30
Last updated
2019-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frail Elderly Syndrome

Keywords

aging, whole body vibration, respiratory muscle training

Brief summary

Aging generates immune, muscular and functional changes. In the pre-frail elderly these changes may be increased and, therefore, preventive interventions are indicated to minimize the consequences of sarcopenia in this population. This study aims to evaluate the effects of a whole body vibration training associated with the training of inspiratory muscles on the inflammatory, muscular and body composition outcomes in pre-frail elderly women.

Interventions

The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.

The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.

Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.

Sponsors

Universidade Federal de Pernambuco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
60 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Elderly individuals able to walk without assistance * Good understanding to carry out the proposed tests, evaluated through the Mini Mental State Examination (MMSE).

Exclusion criteria

* Contraindication or difficulty to perform evaluation procedures * Users of medications that interfere with the cardiovascular and / or muscular system * Smokers * Neuromuscular or degenerative diseases * Pulmonary comorbidities * Heart diseases * Labyrinthitis.

Design outcomes

Primary

MeasureTime frameDescription
Respiratory Muscle Strength and ResistanceChange from Baseline respiratory muscle strength and resistance at 3 monthsMaximum Inspiratory and Expiratory Pressure will be evaluated through manovacuometer

Secondary

MeasureTime frameDescription
Diaphragmatic thicknessChange from Baseline diaphragmatic thickness at 3 monthsUltrasound will to use to evaluate diaphragm thickness non-invasively in the zone of apposition during tidal breathing and with changes in lung volume.
Thickness of the quadriceps muscleChange from Baseline thickness of the quadriceps muscle at 3 monthsUltrasound will be used to assess the thickness of the quadriceps muscle according to the pre-established protocol.
Diaphragmatic mobilityChange from Baseline diaphragmatic mobility at 3 monthsDuring respiration to total lung capacity, measurement of the diaphragmatic excursion will be assessed by ultrasonography.
Body CompositionChange from Baseline body composition at 3 monthsBody composition will be evaluated through bioimpedance balance
Inflammatory markersChange from Baseline inflammatory markers at 3 monthsBlood concentration of Interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha) and brain-derived neurotrophic factor (BDNF) will be assessed through blood plasma sample.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026